SURMOUNT-1 Trial (New England Journal of Medicine, 2022) Randomized, double-blind, placebo-controlled 2,539 participants 72 weeks NCT04184622 Tirzepatide 5 mg -16.0% Mean body weight reduction Tirzepatide 10 mg -21.4% Mean body weight reduction Tirzepatide 15 mg -22.5% Mean body weight reduction Placebo group: -2.4% All results statistically significant (p 27 with Comorbidities Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss
Pros: 1,000 mg per tablet (convenient clinical dose), GMP + NPA A-rated, purest form, 100-count bottle, 55+ year brand, Non-GMO, flexible dosing
Here, you eat normally for five days of the week and drastically reduce your calorie intake on the other two days, consuming only about 500-600 calories
Will alternating GLP-1 medications prevent tolerance